Emergent BioSolutions Inc.
EBS
$8.50
-$0.45-5.03%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 676.80M | 742.90M | 788.90M | 851.60M | 965.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 676.80M | 742.90M | 788.90M | 851.60M | 965.40M |
| Cost of Revenue | 355.60M | 375.80M | 404.80M | 435.40M | 675.40M |
| Gross Profit | 321.20M | 367.10M | 384.10M | 416.20M | 290.00M |
| SG&A Expenses | 180.50M | 186.30M | 195.40M | 233.00M | 266.30M |
| Depreciation & Amortization | 65.30M | 65.10M | 65.10M | 65.10M | 65.20M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 601.00M | 626.80M | 664.50M | 732.50M | 1.01B |
| Operating Income | 75.80M | 116.10M | 124.40M | 119.10M | -40.50M |
| Income Before Tax | 3.50M | 82.80M | 105.90M | 190.70M | -62.30M |
| Income Tax Expenses | 12.10M | 30.20M | 30.00M | 51.20M | 69.30M |
| Earnings from Continuing Operations | -8.60 | 52.60 | 75.90 | 139.50 | -131.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.60M | 52.60M | 75.90M | 139.50M | -131.60M |
| EBIT | 75.80M | 116.10M | 124.40M | 119.10M | -40.50M |
| EBITDA | 167.20M | 209.40M | 220.50M | 217.90M | 62.90M |
| EPS Basic | -0.17 | 0.95 | 1.41 | 2.61 | -2.55 |
| Normalized Basic EPS | 0.22 | 0.62 | 0.78 | 1.10 | -0.89 |
| EPS Diluted | -0.28 | 0.84 | 1.30 | 2.45 | -2.71 |
| Normalized Diluted EPS | 0.16 | 0.55 | 0.71 | 1.02 | -0.97 |
| Average Basic Shares Outstanding | 211.70M | 214.20M | 216.00M | 215.90M | 214.30M |
| Average Diluted Shares Outstanding | 219.60M | 220.40M | 222.20M | 221.30M | 219.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |